Clinical

The approval makes mosunetuzumab the first in its class approved to treat follicular lymphoma and comes shortly after data from a phase 2 trial was presented at the annual meeting of the American Society of Hematology.

Bruce Sherman, MD, FCCP, FACOEM, underlines the impact of health inequities for patients diagnosed with psoriasis.

Maria Lopes, MD, MS, provides an overview of the PASI scoring system.

Amy McMichael, MD, discusses the impact of psoriasis on a patient’s quality of life.

Ryan Haumschild, PharmD, MS, MBA, leads a panel discussion highlighting the current prevalence of psoriasis.

Dr Brinton provides insights regarding prognosis for patients with HoFH.

Eliot Brinton, MD, opens a discussion surrounding the treatment landscape for patients with homozygous familial hypercholesterolemia (HoFH).

The 2022 European Hematology Association (EHA22) Congress convened June 9-12, 2022, in Vienna, Austria, and presented cutting-edge findings in hematology, including the potential of artificial intelligence, new treatment combinations in myelofibrosis, and more.

David Lieberman, MD, PhD, reviews the potential role and the goals of gene therapy in the treatment of Rett syndrome.

In their closing thoughts, experts emphasize their optimism regarding the direction of LN treatment strategies and resources.

Drs Wells and Larranaga discuss unmet needs in the treatment landscape for patients with lupus nephritis.

Adult patients with moderate-to-severe atopic dermatitis (AD) in the phase 3 BREEZE-AD7 study showed sustained improvement of AD signs and symptoms after 68 weeks with combination treatment of bariticitinib and topical corticosteroids.

Drs Larranaga and Wells describe challenges impacting access to care for patients with LN.

A pair of abstracts presented during this year’s 64th American Society of Hematology Annual Meeting and Exposition explored barriers to treatment for sickle cell disease (SCD).

Guillermo Garcia-Manero, MD, highlights the ASCERTAIN trial in his opening thoughts surrounding MDS in this ASH 2022 post-conference perspective.

Carlos M. De Castro, MD, highlights the phase III Apply-PNH study presented at ASH 2022.

Patient education is critical for self-monitoring of COPD disease progression.

An expert panel discusses appropriate transitions and adjustments to COPD treatment approaches.

Medical experts share considerations for early intervention in patients with diagnoses of diabetes.

Medical experts navigate risk factors associated with diabetes.

Ryan Haumschild, PharmD, MS, MBA, leads a panel in a conversation reviewing the MAIA study.

Key opinion leaders open a discussion surrounding the current treatment landscape of multiple myeloma (MM).

In heart failure this year, value-based care, left ventricular ejection fraction, and disease prevention were among the most popular topics discussed.

A pair of abstracts presented at this year’s 64th American Society of Hematology Annual Meeting and Exposition bear out the significant transfusion-free rate at 3 years following beti-cell administration and marked improvements in patient-reported outcomes, including the ability to work and be physically active.

A retrospective study found roxadustat to be more effective in improving hemoglobin levels in patients who had with chronic kidney disease (CKD) compared with recombinant human erythropoietin.

Overall survival for patients with combined hepatocellular-cholangiocarcinoma is poor, but those who received adjuvant transarterial chemoembolization (TACE) after surgery had a prolonged recurrence-free survival (RFS).

This new study, which followed patients up to 6 months after functional endoscopic sinus surgery, evaluated results using objective and subjective measures.

Although rare, stiff person syndrome spectrum disorders can significantly affect patient quality of life, and current knowledge gaps warrant further research.

In her final thoughts regarding gastroesophageal cancer, Laura Bobolts, PharmD, BCOP, overviews patient support services and programs.